...Hi. Welcome to the 40th Annual Canaccord Genuity Global Growth Conference. I'm Max Masucci, lead diagnostics analyst at Canaccord. And I'm pleased to be joined by Exact Sciences, one of the fastest-growing companies in my coverage universe over the past 5 years. And one of the biggest success stories in noninvasive screening for early-stage cancer due to its Cologuard test for colorectal cancer. So despite growing its Cologuard business from under $2 million in revenues in 2014 to over $810 million in 2020, Exact remains just 6% penetrated in its Cologuard opportunity with a stated goal of achieving 40% penetration over time. Beyond Cologuard, Exact has a Precision Oncology segment which it acquired in 2018 through its acquisition of Genomic Health. Exact is a market-leading R&D engine, which we expect to drive shareholder returns equally as spectacularly as what we have seen over the past 5 years. So I'm really pleased to welcome back Exact Sciences CFO, Jeff Elliott; and Megan Jones,...